In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time of surgery. If further validated in larger, confirmatory trials, the oral medication could replace chemotherapy for these patients.
...
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR...
Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable...
Matching targeted therapies to tumor-specific gene mutations across tumor types improved progression-free survival (PFS) and overall survival (OS) in patients with advanced disease relative to those receiving non-matched treatment (NMT), according to research from The University of Texas MD Anderson Cancer Center. The researchers also found that receiving matched targeted therapy (MTT) was an independent factor for predicting longer OS...
The University of Texas MD Anderson Cancer Center today sent letters to individuals whose email addresses were accidentally exposed in a communication...
The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating...
The American Society of Clinical Oncology (ASCO) will present awards to leaders of cancer care during its annual meeting June 1-5 in Chicago...
The University of Texas MD Anderson and Ipsen, a global biopharmaceutical group, today announced a global licensing and joint development...
While some regions of the nation will experience greater nursing shortages than others in the coming years, hospitals and healthcare systems...
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity...
Abstract: 6063
A study led by researchers at The University of Texas MD Anderson Cancer Center found that the use of at-home sensor...
A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical...
Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to...
The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by...